Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.
Phase III fenebrutinib data show reduced chronic active MS lesions and a 55% ARR cut; Ocrevus shows durable pediatric and older-adult control; Enspryng supports MOGAD attack reduction.
Phase III data showed ARR reductions of 51% and 58% vs teriflunomide and a numerical 12% reduction in PPMS progression versus ocrelizumab; CNS‑penetrant, non‑covalent BTK inhibitor.
FENhance 1/2: the BTK inhibitor cut MRI lesion activity vs teriflunomide and showed trends to less disability; PPMS trial non‑inferior to ocrelizumab. Safety: similar LFTs; more deaths.
Fenebrutinib reduced relapses by 51% in RMS, consistent with prior studies. Data will be submitted to regulators. Safety profile comparable to teriflunomide; further analysis on fatalities ongoing.
